Andrea D Thompson
Internal Medicine- Division of Cardiovascular Medicine
1150 W. Medical Center Drive, MSRBIII 7220B
Ann Arbor, MI 48109
Manage Your Profile
About
Andrea D. Thompson, MD/PhD is an Assistant Professor in the Department of Internal Medicine, Division of Cardiovascular Medicine. She received her bachelor’s degree from the Massachusetts Institute of Technology in Cambridge, MA, and her medical degree from the University of Michigan in Ann Arbor, MI. She completed her residency training in Internal Medicine and fellowship training in Cardiovascular Medicine and Critical Care Medicine at the University of Michigan. She joined the faculty in 2022. Dr. Thompson’s clinical work is focused on caring for critically ill cardiac patients in the cardiac intensive care unit. She also sees patients within the inherited cardiomyopathies clinic. She has a particular interest in serving the needs of patients living with genetic cardiomyopathies.
Links
Laboratory Website Google Scholar
Qualifications
-
Critical Care MedicineMichigan Medicine, Ann Arbor, United States
2021 - 2022
Clinical Fellowship
-
Hypertrophic cardiomyopathy ResearchMichigan Medicine, Ann Arbor, United States
2019 - 2021
Postdoctoral Research
-
Cardiovascular DiseaseMichigan Medicine, Ann Arbor, United States
2016 - 2020
Clinical Fellowship
-
Internal MedicineMichigan Medicine, Ann Arbor, United States
2014 - 2016
Residency
-
MDUniversity of Michigan Medical School, Ann Arbor, MI, United States
2006 - 2014
-
PhD- Chemical BiologyUniversity of Michigan, Ann Arbor, MI, United States
2006 - 2014
-
BS - Chemical EngineeringMassachusetts Institute of Technology, Cambridge, MA, United States
2002 - 2006
Center Memberships
-
Center MemberSamuel and Jean Frankel Cardiovascular Center
-
Center MemberFrankel Institute for Heart and Brain Health
Research Overview
Dr. Thompson’s research interests include basic and translational research focused on cardiomyopathies. This includes:
1. Identifying modifiers of disease onset and progression in cardiomyopathies.
2. Uncovering novel disease modifying targets and developing small molecules to treat cardiomyopathies.
3. Defining the molecular mechanisms by which MYBPC3 missense variants lead to hypertrophic cardiomyopathy.
4. Developing strategies to better understand and characterize variants of uncertain significance.
5. Understanding biological pathways which drive recovery after cardiogenic shock.
Recent Publications
-
Hamilton DE, Shriver JL, Patel SM, Park J-G, Michos ZE, Mathis MR, Adie SK, Alviar CL, Barnett CF, Berg DD, Bennett CE, Bohula EA, Carnicelli AP, Daniels LB, Dodson MW, Gage A, Gidwani U, Goldfarb M, Katz JN, Ketcham SW, Kwon Y, Leibner ES, Loriaux DB, Luk A, Marano P, Miller PE, Mukundan SV, Papolos AI, Pisani BA, Proudfoot AG, Roswell RO, Shah KS, Solomon MA, Tomey MI, van Diepen S, Zakaria S, Morrow DA, Thompson AD, CCCTN Investigators . Circ Heart Fail, 2026 Sep; 19 (9): e013778Journal ArticleVariation in Vasoactive Treatment Selection for Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network (CCCTN).
DOI:10.1161/CIRCHEARTFAILURE.125.013778 PMID: PMC13240787 -
Thompson AD, Pankiewicz C, Plenge LS, Lilienthal U, Kotaru S, Vignesh M, Phan T, McAllister C, Yob J, Morley MP, Ingles J, Hespe S, Helms AS, Ginsburg D, SHaRe-HCM Investigators , Day SM. 2026 Jul 20;PreprintPathogenic MYBPC3 missense variants alter protein-protein interactions within the sarcomere.
DOI:10.64898/2026.05.27.727676 PMID: 42327163 -
Thompson AD, Nguyen K, Alhuneafat L, Elliott AM. European Heart Journal Acute Cardiovascular Care, 2026 Jun 1; 15 (6): 484 - 493.Journal ArticleCharting new territories in cardiac care intensive care rehabilitation and the enduring impact on post-acute cardiac event outcomes
DOI:10.1093/ehjacc/zuag070 PMID: 42160216 -
Nguyen K, Dudzinski DM, Dahiya G, Elliott A, Hillerson DB, Isseh I, Thompson AD, Whiteside HL, Sinha SS. Jacc Advances, 2026 Apr 1; 5 (4):Journal ArticlePost-CICU Recovery Programs
DOI:10.1016/j.jacadv.2026.102652 -
Thompson A. 2026 Jul 21;PresentationMYBPC3 as a therapeutic target in HCM.
-
Thompson A. 2026 Jul 21;PresentationDefining the molecular mechanisms of MYBPC3 pathogenic missense variants
-
Thompson A, McAllister C, Turner K. 2026 Jul 21;PresentationDefining the Molecular Mechanisms of MYBPC3 pathogenic missense variants.
-
Thompson A, McAllister C, Turner K. 2026 Jul 21;PresentationDefining the Molecular Mechanisms of MYBPC3 pathogenic missense variants.
Featured News & Stories